Jason Broderick

Cranbury

Associate Editorial Director at Urology Times

Associate Director, Digital Editorial @OncLive

Featured in: Favicon

urologytimes.com Favicon

contagionlive.com Favicon

hcplive.com Favicon

pharmacytimes.com Favicon

cancernetwork.com Favicon

onclive.com Favicon

curetoday.com Favicon

targetedonc.com Favicon

oncnursingnews.com Favicon

newsbreak.com + 3 more

Articles

Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC

2 days ago | targetedonc.com | Jason Broderick

Nadofaragene firadenovec-vncg (Adstiladrin) elicited complete responses (CRs) in three-fourths of Japanese patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), according to initial results from a phase 3 trial shared during the 2025 Japanese Urological Association (JUA) Annual Meeting.1,2The CR rate at 3 months was 75% (n = 15) in this patient population.
Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

1 week ago | targetedonc.com | Jason Broderick

A small, single-center Italian study showed positive signals of efficacy and safety for melphalan flufenamide (melflufen) use in combination with dexamethasone in a real-world setting for patients with relapsed/refractory multiple myeloma,according to findings shared at the 6th European Myeloma Network Meeting in Athens, Greece.1,2 Melflufen is approved in Europe under the trade name Pepaxti for use in this setting; however, in the United States, the FDA withdrew its approval for melflufen...
Nivolumab Plus Ipilimumab Trends Toward Prolonged OS in nccRCC

1 week ago | targetedonc.com | Jason Broderick

The dual-immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a strong clinical benefit at 12 months with a trend toward prolongation of overall survival (OS) vs standard of care (SOC) in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC), according to findings from the phase 2 SUNNIFORECAST study published in the Annals of Oncology.1 At a median follow-up of 21.5 months (range, 0.0 -70.2), the median OS was 33.2 months with...
Neoadjuvant Nivolumab/Chemo Shows Promise in HPV-Negative HNSCC

1 week ago | targetedonc.com | Jason Broderick

Among patients with HPV-negative locoregionally advanced head and neck squamous cell carcinoma (HNSCC), neoadjuvant nivolumab (Opdivo) plus chemotherapy with subsequent response-adapted de-escalated chemoradiation therapy (CRT) elicited promising efficacy with reduced acute toxicity occurring in deep responders.1,2 These results, which come from the phase 2 DEPEND trial (NCT03944915),1 showed that at a median follow-up of 20 months (range, 13-40), 53% (95% CI, 35%-70%) of patients reached a...
Taletrectinib Data Published as FDA Weighs Approval for ROS1+ NSCLC

2 weeks ago | targetedonc.com | Jason Broderick

Pivotal data showing strong clinical activity for taletrectinib in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology, with the FDA currently reviewing a new drug application (NDA) for use of the ROS1 tyrosine kinase inhibitor (TKI) in this setting.1,2The data are from a pooled analysis of the single-arm, open-label, multicenter phase 2 TRUST-I and TRUST-II trials.
Vepdegestrant Improves PFS in ESR1-Mutated Breast Cancer

2 weeks ago | targetedonc.com | Jason Broderick

the risk of disease progression or death vs fulvestrant in patients with estrogen receptor 1-mutant (ESR1m),estrogen receptor–positive/HER2– advanced or metastatic breast cancer with disease progression after treatment with CDK 4/6 inhibitors and endocrine therapy, according to topline results from the phase 3 VERITAC-2 clinical trial (NCT05654623).1 In the ESR1m subgroup, vepdegestrant met part of the primary study end point by significantly improving progression-free survival (PFS) vs...
Novel ADC Shows Promise of Targeting CD46 in mCRPC

3 weeks ago | targetedonc.com | Jason Broderick

FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, had a manageable safety profile and elicited promising preliminary activity in patients with metastatic castration-resistant prostate cancer (mCRPC), according to findings from a phase 1 trial (NCT03575819) published in the Journal of Clinical Oncology.1The median radiographic progression-free survival was 8.7 months (range, 0.1-33.9)among the 40 patients in the efficacy evaluable population.
Zongertinib Shows Antitumor Activity in Patients With HER2-Altered Tumors

4 weeks ago | targetedonc.com | Jason Broderick

The HER2-selective TKI zongertinib was safe and elicited preliminary antitumor activity in patients with HER2-altered tumors, according to results from the ongoing phase 1a/1b Beamion LUNG-1 trial.1,2Results from phase 1a of the trial, which were recently published in the Journal of Clinical Oncology (JCO), showed that across all doses and tumor types, the confirmed investigator-assessed overall response rate (ORR) for zongertinib was 30% (95% CI, 23-40).
mKRAS ctDNA Emerges as Predictor of Metastasis, Survival in PDAC

1 month ago | targetedonc.com | Jason Broderick

The presence of mutant KRAS (mKRAS) circulating tumor DNA (ctDNA) in plasma and peritoneal fluid was associated with increased risk of metastatic progression and worse overall survival in patients with localized pancreatic ductal adenocarcinoma (PDAC); this biomarker now allows for more informed treatment decision making in this patient population.1,2 The findings, which come from a study by researchers at the Mayo Clinic in Rochester, MN, showed that among patients who received baseline...
Pembrolizumab Plus Bevacizumab Shows Promise for Melanoma Brain Metastases

1 month ago | targetedonc.com | Jason Broderick

Anti-VEGF therapy with bevacizumab (Avastin) appeared to enhance the clinical activity of the PD-1 inhibitor pembrolizumab (Keytruda) in patients with untreated melanoma brain metastases (MBM), according to findings from a phase 2 study (NCT02681549) published in the Journal of Clinical Oncology.1The combination led to a brain metastasis response rate—the primary end point of the study—of 54.1% (95% CI, 36.9-70.5) and an extracranial response rate of 56.3% (95% CI, 37.7-73.6).